menu
    • menu

    Company profile for Areteia Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Today, our team is focused on a single goal: To develop the first oral drug for eosinophilic asthma.Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Areteia TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    101 Glen Lennox Dr Suite 300 Chapel Hill, NC 27517
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://areteiatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Areteia Posts Ph. 3 Asthma Win for Oral Rival to Biologic Drugs
    Areteia Posts Ph. 3 Asthma Win for Oral Rival to Biologic Drugs

    17 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250916566261/en/Areteia-Therapeutics-Announces-Positive-Topline-Results-from-the-First-Phase-III-Study-of-Oral-Dexpramipexole-in-Eosinophilic-Asthma

    BUSINESSWIRE
    17 Sep 2025
    Share Share
    Areteia Reports Positive Ph 3 Dexpramipexole Results In Asthma
    Areteia Reports Positive Ph 3 Dexpramipexole Results In Asthma

    16 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-16/areteia-therapeutics-announces-positive-topline-results-from-the-first-phase-iii-study-of-oral-dexpr

    PHARMAWEB
    16 Sep 2025
    Share Share
    Areteia Therapeutics Appoints Donald J. Hayden, Jr. and Ian F. Sm
    Areteia Therapeutics Appoints Donald J. Hayden, Jr. and Ian F. Sm

    26 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250326335483/en/Areteia-Therapeutics-Announces-Appointments-of-Donald-J.-Hayden-Jr.-and-Ian-F.-Smith-to-Its-Board-of-Directors

    BUSINESSWIRE
    26 Mar 2025
    Share Share
    Areteia To Present At 43rd J.P. Morgan Healthcare Conference Jan 14
    Areteia To Present At 43rd J.P. Morgan Healthcare Conference Jan 14

    09 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250109198891/en

    BUSINESSWIRE
    09 Jan 2025
    Share Share
    Areteia Announces Appointment of Daniel Becker To Board of Directors
    Areteia Announces Appointment of Daniel Becker To Board of Directors

    15 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240215803782/en

    BUSINESSWIRE
    15 Feb 2024
    Share Share
    Areteia Therapeutics Announces Additional $75MM in Series A Financing
    Areteia Therapeutics Announces Additional $75MM in Series A Financing

    13 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240213672000/en

    BUSINESSWIRE
    13 Feb 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

    Details:

    Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 01, 2024

    blank

    01

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

    Details : Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    August 01, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase III Long-Term Extension Study With Dexpramipexole

    Details:

    Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 29, 2024

    blank

    02

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase III Long-Term Extension Study With Dexpramipexole

    Details : Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 29, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Areteia Raises $75MM for Oral Dexpramipexole in Eosinophilic Asthma

    Details:

    The funding will be used to support the Phase III clinical development of dexpramipexole. It is an eosinophil maturation inhibitor that will be used in the treatment of Eosinophilic Asthma.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Viking Global Investors

    Deal Size: $425.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing February 13, 2024

    blank

    03

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Viking Global Investors

    Deal Size : $425.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Areteia Raises $75MM for Oral Dexpramipexole in Eosinophilic Asthma

    Details : The funding will be used to support the Phase III clinical development of dexpramipexole. It is an eosinophil maturation inhibitor that will be used in the treatment of Eosinophilic Asthma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    February 13, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

    Details:

    Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 14, 2023

    blank

    04

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic ...

    Details : Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 14, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

    Details:

    Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 10, 2023

    blank

    05

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic ...

    Details : Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 10, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma

    Details:

    Dexpramipexole dihydrochloride inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. It is being developed for moderate-to-severe eosinophilic asthma.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 09, 2023

    blank

    06

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosino...

    Details : Dexpramipexole dihydrochloride inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. It is being developed for moderate-to-severe e...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 09, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

    Details:

    Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.


    Lead Product(s): Dexpramipexole

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 28, 2023

    blank

    07

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Areteia Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexpramipexole

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

    Details : Dexpramipexole Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Eosinophilia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 28, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search